{"id":"lenalidomide-dexamethasone-pbsct","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Peripheral neuropathy"},{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Insomnia"},{"rate":null,"effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL848","moleculeType":"Small molecule","molecularWeight":"259.26"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Lenalidomide is an immunomodulatory agent that activates T cells and natural killer cells while inducing direct cytotoxicity in multiple myeloma cells. Dexamethasone is a corticosteroid that enhances lenalidomide's anti-myeloma effects and provides additional immunosuppression. PBSCT (peripheral blood stem cell transplantation) is a supportive procedure that allows for high-dose chemotherapy and restoration of hematopoietic function.","oneSentence":"Lenalidomide enhances immune cell activity and promotes apoptosis of myeloma cells, while dexamethasone provides anti-inflammatory and anti-tumor effects, followed by peripheral blood stem cell transplantation to restore bone marrow function.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:18:30.137Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Multiple myeloma (newly diagnosed or relapsed/refractory)"}]},"trialDetails":[{"nctId":"NCT01208662","phase":"PHASE3","title":"Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65","status":"ACTIVE_NOT_RECRUITING","sponsor":"Paul Richardson, MD","startDate":"2010-09","conditions":"Multiple Myeloma","enrollment":729},{"nctId":"NCT01936532","phase":"PHASE2","title":"Safety and Efficacy Study of a Triplet Combination of MLN9708, Lenalidomide and Dexamethasone in the Initial Management of Multiple Myeloma (IFM2013-06)","status":"COMPLETED","sponsor":"Nantes University Hospital","startDate":"2014-11-12","conditions":"Newly Diagnosed Multiple Myeloma","enrollment":42},{"nctId":"NCT01090089","phase":"PHASE3","title":"Combination of Lenalidomide and Dexamethasone in Treatment of Multiple Myeloma","status":"COMPLETED","sponsor":"Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH","startDate":"2010-03-01","conditions":"Multiple Myeloma","enrollment":348},{"nctId":"NCT02415413","phase":"PHASE2","title":"Carfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"PETHEMA Foundation","startDate":"2015-05","conditions":"Smoldering Multiple Myeloma","enrollment":90},{"nctId":"NCT02128230","phase":"PHASE2","title":"UARK 2012-02 Trial For High-Risk Myeloma Evaluating Accelerating and Sustaining Complete Remission","status":"TERMINATED","sponsor":"University of Arkansas","startDate":"2014-06-10","conditions":"Multiple Myeloma","enrollment":20},{"nctId":"NCT01731886","phase":"PHASE4","title":"Lenalidomide and Dexamethasone With/Without Stem Cell Transplant in Patients With Multiple Myeloma","status":"COMPLETED","sponsor":"Columbia University","startDate":"2012-09","conditions":"Multiple Myeloma","enrollment":60},{"nctId":"NCT02655458","phase":"PHASE1","title":"Elotuzumab in Autologous Stem Cell Transplantation (ASCT) and Lenalidomide Maintenance for Multiple Myeloma","status":"COMPLETED","sponsor":"Hearn Jay Cho","startDate":"2016-01","conditions":"Multiple Myeloma","enrollment":15}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Revlimid"],"phase":"phase_3","status":"active","brandName":"Lenalidomide, Dexamethasone, PBSCT","genericName":"Lenalidomide, Dexamethasone, PBSCT","companyName":"Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH","companyId":"gesellschaft-fur-medizinische-innovation-hamatologie-und-onkologie-mbh","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Lenalidomide enhances immune cell activity and promotes apoptosis of myeloma cells, while dexamethasone provides anti-inflammatory and anti-tumor effects, followed by peripheral blood stem cell transplantation to restore bone marrow function. Used for Multiple myeloma (newly diagnosed or relapsed/refractory).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}